Enzo Biochem to Report First Quarter 2022 Financial Results and Business Update on Wednesday, December 15th
Enzo Biochem, Inc. (NYSE:ENZ) announced it will release its financial results for the first quarter of 2022 on December 15, 2021, after market close. Following this, a live audio webcast and conference call are scheduled at 4:30 pm ET. The company continues to innovate in molecular diagnostics, leveraging its intellectual property portfolio to meet healthcare needs. For more information, the press release provides a registration link for the conference call, encouraging stakeholders to join and learn about the company's performance and outlook.
- None.
- None.
Conference Call and Webcast Scheduled for December 15, 2021, 4:30 pm ET
NEW YORK, NY, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report first quarter 2022 financial results on Wednesday, December 15, 2021, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 pm Eastern Time.
Wednesday, December 15th @ 4:30 pm ET
Domestic: 877-407-0792
International: 201-689-8263
Conference ID: 13725234
Webcast: Registration Link -- Click Here
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
For more information, please visit Enzo.com or follow Enzo Biochem on Twitter and LinkedIn.
Forward-Looking Statements
Except for historical information, the matters discussed in this release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2021. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.
###
Contact:
For Enzo Biochem, Inc.
David Bench, CFO
212-583-0100
dbench@enzo.com
Investors:
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com
Steve Anreder
Anreder & Company
212-532-3232
Steven.anreder@anreder.com
Media:
Lynn Granito
Berry & Company Public Relations
212-253-8881
lgranito@berrypr.com
FAQ
What are Enzo Biochem's Q1 2022 financial results release date?
When is the conference call for Enzo Biochem's Q1 2022 results?
How can I access the Enzo Biochem Q1 2022 earnings webcast?
What is Enzo Biochem's focus in the diagnostics industry?
